-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Minneapolis, November 3, 2021/PRNewswire/—Bio-Techne Inc.
As described in a recent article in the journal Nature, in 2021, there will be more than 1,300 cell therapy clinical trials in progress globally, an increase of 43% over the previous year
Chuck Kummeth, President and CEO of Bio-Techne, commented: "Bio-Techne is a global leader in research-grade proteins and has recently experienced rapid growth in gmp-grade proteins
For more information about Bio-Techne's cell and gene therapy workflow product portfolio, please visit
About Bio-Techne (NASDAQ:TECH)
Contact: David Clair, Senior Director of Investor Relations and Corporate Development david.
Source Bio-Techne